Bio Green Med Solution, Inc.BGMS
Price (close)
$0.92
Market cap
$6.1M
P/E
—
Revenue (TTM)
$1.8M
Net income
-$2.2M
Dividend yield
—
1-year total return
-80.6%
Net margin
-119.2%
Revenue growth
—
Debt / equity
—
What Bio Green Med Solution, Inc. does.
following Business Section contains forward-looking statements. Our actual results could differ materially from those anticipated in
these forward-looking statements as a result of certain risks, uncertainties and other factors including the risk factors set forth in
as Cyclacel Pharmaceuticals, Inc., announced that it was in the process of exploring and reviewing strategic alternatives on an expedited
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $420,000 | $43,000 | $0 |
| Net income | -$8.4M | -$18.5M | -$21.2M | -$22.6M | -$11.2M | -$3.0M |
| Free cash flow | -$8.0M | -$18.6M | -$20.8M | -$16.1M | — | — |
More on BGMS.
- Bio Green Med Solution, Inc. summary
- Bio Green Med Solution, Inc. financial statements
- Bio Green Med Solution, Inc. key metrics
- Bio Green Med Solution, Inc. health scores and style box
- Bio Green Med Solution, Inc. earnings
- Bio Green Med Solution, Inc. dividends
- Bio Green Med Solution, Inc. valuation
- Bio Green Med Solution, Inc. ownership and insiders
- Bio Green Med Solution, Inc. peers
Figures from Bio Green Med Solution, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.